Canaccord keeps a Buy rating on Veru (VERU) with a $25 price target after the company disclosed a supply agreement with Novo Nordisk (NVO) for Wegovy. The news is a "significant event" for Veru as it shows enobosarm has "grabbed the attention of one of the two players in obesity," the analyst tells investors in a research note. Canaccord views Veru's data to date as "compelling" and believes enobosarm could be a "significant differentiator." Shares of Veru are up 154%, or $3.43, to $5.68 in midday trading.
